Remdesivir: Preliminary Data and Clinical Use Versus Recommended Use.
作者信息
Boutzoukas Angelique E, Benjamin Daniel K, Zimmerman Kanecia O
机构信息
Duke Clinical Research Institute and Department of Pediatrics, School of Medicine, Duke University, Durham, North Carolina.
Duke Clinical Research Institute and Department of Pediatrics, School of Medicine, Duke University, Durham, North Carolina
出版信息
Pediatrics. 2021 May;147(5). doi: 10.1542/peds.2021-050212.
Abstract
摘要
相似文献
1
Remdesivir: Preliminary Data and Clinical Use Versus Recommended Use.
Pediatrics. 2021 May;147(5). doi: 10.1542/peds.2021-050212.
2
Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 Therapy.瑞德西韦和GS-441524在持续低效血液透析（PIRRT）和Seraph 100治疗期间的药代动力学
Clin J Am Soc Nephrol. 2021 Aug;16(8):1256-1257. doi: 10.2215/CJN.17601120. Epub 2021 Jul 23.
3
Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir.接受血液透析的COVID-19患者的治疗：瑞德西韦的疗效。
Nefrologia (Engl Ed). 2023 Dec;43 Suppl 2:112-113. doi: 10.1016/j.nefroe.2022.07.008. Epub 2023 Jan 25.
4
An updated meta-analysis of pooled incidence of remdesivir-associated bradycardia.
J Med Virol. 2024 Apr;96(4):e29584. doi: 10.1002/jmv.29584.
5
Emergency Use Authorization for Remdesivir and Its Potential Implications.瑞德西韦的紧急使用授权及其潜在影响。
Ther Innov Regul Sci. 2021 Mar;55(2):270-271. doi: 10.1007/s43441-020-00212-5. Epub 2020 Sep 3.
6
COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.2019冠状病毒病最新情况：瑞德西韦（Veklury）用于高危2019冠状病毒病门诊患者。
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-32.
7
Should remdesivir be recommended in France in the early stage of COVID-19.在法国，新冠病毒病（COVID-19）早期阶段是否应推荐使用瑞德西韦？
Int J Infect Dis. 2022 Mar;116:281-282. doi: 10.1016/j.ijid.2021.12.359. Epub 2022 Jan 2.
8
Timing of remdesivir for COVID-19.瑞德西韦用于治疗新冠肺炎的时机。
Med Lett Drugs Ther. 2020 Oct 19;62(1609):161.
9
A Potential Antiviral Treatment for COVID-19: Remdesivir.一种针对新冠病毒病的潜在抗病毒疗法：瑞德西韦。
Clin Nurse Spec. 2020 Nov/Dec;34(6):257-260. doi: 10.1097/NUR.0000000000000549.
10
Assessing the evidence on remdesivir.评估关于瑞德西韦的证据。
Lancet Infect Dis. 2021 Dec;21(12):1630-1631. doi: 10.1016/S1473-3099(21)00695-2.
本文引用的文献
1
Compassionate Use of Remdesivir in Children With Severe COVID-19.瑞德西韦在儿童严重 COVID-19 中的同情使用。
Pediatrics. 2021 May;147(5). doi: 10.1542/peds.2020-047803.
2
SARS-CoV-2 infections in children and young people.儿童和青少年感染 SARS-CoV-2。
Clin Immunol. 2020 Nov;220:108588. doi: 10.1016/j.clim.2020.108588. Epub 2020 Sep 6.
3
Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020.**儿童**：<18 岁，**实验室确诊** COVID-19 住院率及特征——COVID-NET，14 个州，2020 年 3 月 1 日-7 月 25 日。
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1081-1088. doi: 10.15585/mmwr.mm6932e3.
4
The journey of remdesivir: from Ebola to COVID-19.瑞德西韦的历程：从埃博拉到新冠病毒。
Drugs Context. 2020 May 22;9. doi: 10.7573/dic.2020-4-14. eCollection 2020.
5
Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.模拟评估治疗儿童 COVID-19 的新型治疗方法的药代动力学指导剂量。
JAMA Pediatr. 2020 Oct 1;174(10):e202422. doi: 10.1001/jamapediatrics.2020.2422. Epub 2020 Oct 5.
6
Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19.瑞德西韦：对其发现与研发历程的综述，该历程促成了其用于治疗新冠病毒病的紧急使用授权
ACS Cent Sci. 2020 May 27;6(5):672-683. doi: 10.1021/acscentsci.0c00489. Epub 2020 May 4.
7
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
8
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
9
Extrapolation of adult data and other data in pediatric drug-development programs.在儿科药物开发计划中，对成人数据和其他数据的外推。
Pediatrics. 2011 Nov;128(5):e1242-9. doi: 10.1542/peds.2010-3487. Epub 2011 Oct 24.
Zotero 插件